DefinePK

Abstract

The novel Coronavirus SARS-CoV-2 that broke out in December 2019 became  the main source of morbidity and mortality around the world. As efficient vaccines and medicines started to emerge , it became  necessary  to recognize and proactively deal with the long term respiratory difficulties that arise due to  extreme illness.  Patients with extreme Coronavirus pneumonia have the tendency of  advancing to  Interstitial Lung Diseases (ILD) and persistent pulmonary vascular disease. In this paper, we shortly review the  pathophysiology of interstitial lung disease (ILD),  lung injury resulting from serious Coronavirus disease. We also outline the  potential viral and secure  intervention  processes for  stopping the advancement of Post-Coronavirus pulmonary Fibrosis (PCPF). Post-Coronavirus pulmonary fibrosis is presently treated in only symptomatic patients, which is, to a great extent, a  neglected perspective. Before  this lethal illness can be treated, it has to be fully researched clinically in order to  know its danger  in Coronavirus survivors. Strong clinical and research biomarkers ought to be considered in order to know  the subgroup of patients that will deteriorate or advance to post Coronavirus interstitial lung disease. Customized medication is a decent method that can be used to treat   patients with Post Coronavirus interstitial lung diseases.